By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


New 'flexible' treatment option for rheumatoid arthritis

A subcutaneous formulation of tocilizumab (RoActemra) has been launched, giving rheumatoid arthritis patients the option to be treated at home as well as hospital.

It is the first anti IL-6 receptor inhibitor available in a subcutaneous and intravenous version, for use with or without methotrexate.

Tocilizumab is licenced for intravenous use every four weeks and the subcutaneous formulation is administered once a week via a pre-filled syringe.

The most common adverse reactions reported in clinical studies were upper respiratory tract infection, nasopharyngitis, headache, elevated blood pressure, and increased liver enzymes.

Ailsa Bosworth, chief executive of the National Rheumatoid Arthritis Society, said: “We welcome this new option which provides greater flexibility and choice for people with rheumatoid arthritis giving them the freedom to carry on with their day-to-day lives.”

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!